Related Experiment Video
Updated: Jun 9, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Clogged Arteries, Safety Net Holes: Treating an Underinsured Patient for Homozygous Familial Hypercholesterolemia
Parth Patel1,2, Iheoma Alinnor1,2, Mary Ann Kirkconnell Hall1
1Division of Hospital Medicine, Emory University School of Medicine, Atlanta, USA.
Abstract:
This case report explores the difficulties with rapid lipid-lowering therapies in a resource-limited setting. We present a case of an individual with previously diagnosed homozygous familial hypercholesterolemia presenting with anginal chest pain concerning for non-ST elevation myocardial infarction (NSTEMI), with a low-density lipoprotein (LDL) of 984 mg/dL (reference range: 100-129 mg/dL) and a reversible perfusion defect on his nuclear medicine stress test. In addition to the standard treatment for NSTEMI, including cardiac catheterization, the patient was initiated on a proprotein convertase subtilisin/kexin type 9 inhibitor and underwent two rounds of plasmapheresis, which effectively and rapidly lowered his LDL levels.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy

